Award
NIH Reporter #7R01CA252049-05
Development of A HTLV-1 Vaccine
Recipient
Not Specified
Award Amount
$601,378.00
Ceiling
$601,378.00
Awarded
September 04, 2025
Identifier
7R01CA252049-05
Award for developing a vaccine targeting HTLV-1 associated diseases using VSV-based vectors, including immunogenicity and efficacy testing in models.
Description
This project aims to develop a vaccine to prevent and treat Human T cell leukemia virus type-1 (HTLV-1) associated diseases, including Adult T cell leukemia/lymphoma (ATLL) and HAM/TSP. The vaccine utilizes VSV-based vectors expressing HTLV-1 glycoprotein and regulatory proteins TAX and HBZ. The research includes evaluating immunogenicity in murine models and testing the vaccine's efficacy in preventing HTLV-1 related leukemia/lymphoma.